As we wrap up 2021, we would like to thank our employees for giving back to our communities around the world. Despite the continued challenges of the pandemic, you continued to show up with participation in our giving and volunteering program.
The Illumina Cares program provides giving opportunities and encourages employees to volunteer in their local communities. We match employee donations, offer paid volunteer time off, and support a volunteer rewards program to earn giving dollars for each hour of volunteer work.
COVID-19 inflicted tremendous suffering in 2021, taking almost 3.5 million lives this year, more than died from HIV/AIDS, tuberculosis and malaria combined last year. We will never forget the loss and pain of this year. But 2021 will also be remembered for the heroic actions of many, and the major medical breakthroughs that were accelerated by the extreme urgency of the pandemic.
Ridhi Tariyal of NextGen Jane joins a wave of female founders using genomics to drive the FemTech industry
When entrepreneur Ridhi Tariyal walked out of Boston’s Brigham & Women’s Hospital in the fall of 2013, she left feeling frustrated. The first reason was she did not get the information she was seeking; her ob-gyn had told her that was the only place she could find the hormone testing she wanted to evaluate her fertility. (At age 33, Tariyal wasn’t trying to get pregnant; she just wanted reassurance that her reproductive system was in good shape.) She was annoyed that the medical system made it this hard for a woman to find out some basic information about her own body.
Delaware State and Testing for America's safety strategy provides model
DOVER, Del., December 20, 2021 /3BL Media/ -- A new research study on how frequent COVID testing coupled with other safety measures enabled a historically Black college to safely remain open even as many other universities shut down their campuses has been published Monday by the JAMA Network Open, a member of JAMA Network.
Barely four months into launching, the core team at Kasturba Hospital’s genome sequencing lab landed their biggest mission. Meet the women playing a critical role in Maharashtra’s fight against COVID’s latest variant
Study to assess the efficacy of blood-based comprehensive genomic profiling (CGP) in cancer therapy selection testing
SAN DIEGO, December 17, 2021 /3BL Media/ -- Illumina, Inc. (NASDAQ:ILMN), announced that it is supporting a national precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling (CGP) in cancer therapy selection testing. The study will also evaluate the cost-effectiveness of implementing blood-based CGP in the public healthcare system.
The health and economic challenges resulting from the COVID-19 pandemic, though daunting, have also created extraordinary opportunities for reinvention. In the life sciences and health care industries in particular, the pressures and expectations driven by the pandemic have, in many cases, accelerated innovation.
San Diego-based molecular diagnostics company PetDx wants to help your four-legged friend
In early 2019, Daniel Grosu found himself dealing with compounding personal crises: he had relocated his parents, who were both recently diagnosed with cancer, from Arizona so they could receive care at the University of California, San Diego (UCSD). Then, in April, his beloved dog, Poppy, received an equally devastating diagnosis: she had advanced pancreatic cancer. Poppy, an 8-pound, mixed-breed rescue, had a long life ahead of her—she was only four. But her disease progressed quickly.
We are delighted that Illumina is the top ranked Healthcare and Life Science company and #2 overall on Newsweek’s America’s Most Responsible Companies 2022 list, which recognizes top-performing companies that are making a difference through their environmental, social and governance actions.